期刊
PHARMACOLOGICAL RESEARCH
卷 61, 期 1, 页码 14-26出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.phrs.2009.10.002
关键词
Neurotrophic factor; Neurodegeneration; Gene therapy; Viral vector; Adeno-associated virus; AAV; Lentivirus; Herpes virus; HSV; Adenovirus; Parkinson's disease; Alzheimer's disease; Amyotrophic lateral sclerosis; Stroke; Epilepsy; Huntington's disease; Central nervous system; Transgene; Clinical trial
资金
- Intramural Research Program at the National Institute on Drug Abuse.
- NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000443, ZICDA000555] Funding Source: NIH RePORTER
The clinical manifestation of most diseases of the central nervous system results from neuronal dysfunction or loss. Diseases such as stroke, epilepsy and neurodegeneration (e.g. Alzheimer's disease and Parkinson's disease) share common cellular and molecular mechanisms (e.g. oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction) that contribute to the loss of neuronal function. Neurotrophic factors (NTFs) are secreted proteins that regulate multiple aspects of neuronal development including neuronal maintenance, survival, axonal growth and synaptic plasticity. These properties of NTFs make them likely candidates for preventing neurodegeneration and promoting neuroregeneration. One approach to delivering NTFs to diseased cells is through viral vector-mediated gene delivery. Viral vectors are now routinely used as tools for studying gene function as well as developing gene-based therapies for a variety of diseases. Currently, many clinical trials using viral vectors in the nervous system are underway or completed, and seven of these trials involve NTFs for neurodegeneration. In this review, we discuss viral vector-mediated gene transfer of NTFs to treat neurodegenerative diseases of the central nervous system. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据